David J. Lederer

Cornell University — United States

Medicine · Health Sciences

71h-index32.3kcitations460works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis(161), Transplantation: Methods and Outcomes(141), Organ Transplantation Techniques and Outcomes(70), Chronic Obstructive Pulmonary Disease (COPD) Research(63), Asthma and respiratory diseases(61)

Publications451 total

High density lipoproteins, disease severity and clinical outcomes in patients with idiopathic pulmonary fibrosis
Respiratory Research·2026Open Access
Clinical utility of lung biopsy in fibrotic interstitial lung disease
American Journal of Respiratory and Critical Care Medicine·2026
Association of obstructive sleep apnea with soluble biomarkers of lung and vascular injury: the multi-ethnic study of atherosclerosis
SLEEP·2024· 1 citedOpen Access
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma
The Journal of Allergy and Clinical Immunology In Practice·2024· 26 citedOpen Access
Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE)
The Journal of Allergy and Clinical Immunology In Practice·2024· 8 cited
Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics
The Journal of Allergy and Clinical Immunology In Practice·2024· 2 citedOpen Access
Long-Term Efficacy of Dupilumab in Moderate-to-Severe Asthma Phenotyped by Blood Eosinophils and Exhaled Nitric Oxide
CHEST Pulmonary·2024Open Access
PP-079 Dupilumab in children with moderate-to-severe asthma on medium/high-dose ICS
2024Open Access
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD
ERJ Open Research·2024· 22 citedOpen Access
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma
Journal of Allergy and Clinical Immunology·2024· 43 citedOpen Access
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma
Respiratory Medicine·2024· 6 citedOpen Access
Digital measurement of mobility in pulmonary arterial hypertension: A structured review of an emerging area
Digital Health·2024Open Access
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study
The Journal of Allergy and Clinical Immunology In Practice·2023· 22 citedOpen Access
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study
The Lancet Respiratory Medicine·2023· 44 cited
Efficacy of dupilumab in patients with uncontrolled, moderate‐to‐severe asthma with fungal sensitization
Clinical & Experimental Allergy·2023· 4 citedOpen Access
Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
European Respiratory Journal·2023· 37 citedOpen Access
IL-33 Expression Is Lower in Current Smokers at both Transcriptomic and Protein Levels
American Journal of Respiratory and Critical Care Medicine·2023· 30 citedOpen Access
Dupilumab in Asia-Pacific patients with persistent asthma
2023
Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose
Allergy·2023· 10 citedOpen Access
Incidence of interstitial lung abnormalities: the MESA Lung Study
European Respiratory Journal·2023· 30 citedOpen Access
page 1 of 23Next →

Frequent Co-authors

Joshua Sonett(11), Selim M. Arcasoy(11), Ganesh Raghu(10), Steven M. Kawut(10), Jason D. Christie(10), Steven D. Nathan(9), Scott M. Palmer(8), Ulrich Costabel(8), Christopher J. Ryerson(7), Fernando J. Martínez(7), Harold R. Collard(7), Ian Glaspole(7), Lisa Lancaster(7), Jeffrey J. Swigris(7), Paul W. Noble(7), Joshua M. Diamond(7), F. D’Ovidio(7), Luca Richeldi(6), Athol U. Wells(6), Kevin M. Brown(6)